Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of triple negative breast cancer or colorectal cancer with liver metastases with anti pd-l1 antibody and oncolytic virus

A PD-L1, colorectal cancer technology, applied in the direction of antibody medical components, double-stranded DNA virus, antibodies, etc.

Pending Publication Date: 2020-06-05
AMGEN INC +1
View PDF50 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] While immunotherapy is an effective approach in cancer therapy, such therapies appear to be effective only in a certain percentage of cancer patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of triple negative breast cancer or colorectal cancer with liver metastases with anti pd-l1 antibody and oncolytic virus
  • Treatment of triple negative breast cancer or colorectal cancer with liver metastases with anti pd-l1 antibody and oncolytic virus
  • Treatment of triple negative breast cancer or colorectal cancer with liver metastases with anti pd-l1 antibody and oncolytic virus

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0206] This example demonstrates an exemplary approach to the treatment of patients with triple negative breast cancer or colorectal cancer with liver metastases.

[0207] A phase 1b study was conducted to determine the safety of the combination of intrahepatic injection of latalimoxime to liver metastases with intravenous administration of atezolizumab in patients with triple-negative breast or colorectal cancer, as determined by dose-limiting The incidence of toxicity (DLT) was determined. This study was also conducted to evaluate the efficacy of the combination of latalimogene and atezolizumab, respectively, in subjects with metastatic triple-negative breast cancer or metastatic colorectal cancer with liver metastases, as determined by the following Each item was evaluated: objective response rate (ORR), best overall response (BOR), duration of response (DOR) of cohorts (triple-negative breast cancer and colorectal cancer), injected and uninjected tumor lesions (overall, li...

example 2

[0223] This example describes an exemplary method of measuring tumor lesions particularly in the context of the study described in Example 1 and additional parameters for assessing the efficacy of treatment.

[0224] Computed tomography scan (or magnetic resonance imaging):

[0225] Computed tomography (CT) scans with contrast enhancement or helical scans (or magnetic resonance imaging [MRI] scans) are performed to assess tumor response in visceral or nodal / soft tissue disease, including lymph nodes. The measurability of lesions on CT scans is based on the assumption that CT slice thicknesses are 5 mm or less. If used throughout the study, MRI may be used to assess the extent of disease.

[0226] Each identified and reported lesion can be characterized at baseline and during follow-up using the same method of assessment and the same technique. Switching from contrast-enhanced CT to non-contrast CT or to MRI (or vice versa) did not preclude response assessment if, in the judg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

Provided herein are methods of treating a subject with triple negative breast cancer or colorectal cancer. In exemplary embodiments, the method comprises administering to the subject a combination ofan oncolytic virus, such as talimogene laherparepvec, and an anti-PD-Ll antibody, such as atezolizumab. In exemplary aspects, the oncolytic virus is administered to the subject at an initial dose followed by a second dose, wherein the initial dose is lower than the second dose. In exemplary aspects, the oncolytic virus is intrahepatically administered to the subject.

Description

[0001] Cross References to Related Applications [0002] The benefit of U.S. Provisional Patent Application No. 62 / 542,046, filed August 7, 2017, is hereby claimed under 35 U.S.C. § 119(e), the disclosure of which is hereby incorporated by reference. [0003] Incorporating electronically submitted material by reference [0004] Incorporated by reference in its entirety is the computer-readable nucleotide / amino acid sequence listing filed concurrently with this document, identified as follows: 23 kilobyte ACII (text) filename "51358A_Seqlisting.txt"; created July 23, 2018 day. Background technique [0005] The incidence of breast cancer varies worldwide, and the mortality rate is between 10 and 20 per 100,000 women in most regions of the world (Youlden et al., 2012). According to the Surveillance, Epidemiology, and End Results (SEER) program, approximately 232,000 women are diagnosed with breast cancer and 40,290 women die from breast cancer each year in the United States. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K35/768C07K16/28A61P35/04
CPCA61K39/395C07K16/2827A61K35/763C12N2710/16632A61K2300/00A61P35/00A61K9/0019A61K35/768A61K39/3955A61K2039/505
Inventor J.L.甘塞特S.S.巴塔J.P.伍达德E.N.查
Owner AMGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com